Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;23(5):527-528.
doi: 10.1016/S1473-3099(23)00181-0. Epub 2023 Mar 29.

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster

Qian Wang  1 , Anthony Bowen  2 , Anthony R Tam  3 , Riccardo Valdez  4 , Emily Stoneman  5 , Ian A Mellis  6 , Aubree Gordon  7 , Lihong Liu  1 , David D Ho  8
Affiliations

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster

Qian Wang et al. Lancet Infect Dis. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

QW and AB contributed equally. AG, LL, and DDH were joint senior authors. DDH is a cofounder of TaiMed Biologics and RenBio and a board director for Vicarious Surgical. DDH also serves as a consultant to WuXi Biologics, Brii Biosciences, and Very, and receives funding from Regeneron. AG is a member of a scientific advisory board for Janssen Pharmaceuticals. All other authors declare no competing interests.

Figures

Figure
Figure
SARS-CoV-2 NAb responses following bivalent or monovalent booster vaccination or BA.5 breakthrough infection Bold values indicate significant differences. The number of samples at or below the assay limit of detection (ie, the dotted line) is denoted above the x-axis. (A) Peak serum-neutralising ID50 titres at nearly 1 month after a monovalent booster, bivalent booster, or BA.5 breakthrough. (B) Serum-neutralising ID50 titres at ∼ 3 months for the three cohorts.
See this image and copyright information in PMC

Comment in

References

    1. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286. - PMC - PubMed
    1. US Food and Drug Administration Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. Aug 31, 2023. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...
    1. Collier AY, Miller J, Hachmann NP, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388:565–567. - PMC - PubMed
    1. Wang Q, Bowen A, Valdez R, et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N Engl J Med. 2023;388:567–569. - PMC - PubMed
    1. Lasrado N, Collier AY, Miller J, et al. Waning immunity against XBB.1·5 following bivalent mRNA boosters. bioRxiv. 2023 doi: 10.1101/2023.01.22.525079. published online Jan 23. (preprint). - DOI